U.S. Markets closed

Should You Worry About AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Pay?

Simply Wall St

Jim Clemmer has been the CEO of AngioDynamics, Inc. (NASDAQ:ANGO) since 2016. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then we'll look at a snap shot of the business growth. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. This process should give us an idea about how appropriately the CEO is paid.

See our latest analysis for AngioDynamics

How Does Jim Clemmer's Compensation Compare With Similar Sized Companies?

At the time of writing, our data says that AngioDynamics, Inc. has a market cap of US$620m, and reported total annual CEO compensation of US$3.0m for the year to May 2019. We think total compensation is more important but we note that the CEO salary is lower, at US$687k. Importantly, there may be performance hurdles relating to the non-salary component of the total compensation. We examined companies with market caps from US$400m to US$1.6b, and discovered that the median CEO total compensation of that group was US$2.5m.

So Jim Clemmer receives a similar amount to the median CEO pay, amongst the companies we looked at. This doesn't tell us a whole lot on its own, but looking at the performance of the actual business will give us useful context.

The graphic below shows how CEO compensation at AngioDynamics has changed from year to year.

NasdaqGS:ANGO CEO Compensation, January 4th 2020

Is AngioDynamics, Inc. Growing?

Over the last three years AngioDynamics, Inc. has grown its earnings per share (EPS) by an average of 42% per year (using a line of best fit). Its revenue is up 14% over last year.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's also good to see decent revenue growth in the last year, suggesting the business is healthy and growing. It could be important to check this free visual depiction of what analysts expect for the future.

Has AngioDynamics, Inc. Been A Good Investment?

Since shareholders would have lost about 1.6% over three years, some AngioDynamics, Inc. shareholders would surely be feeling negative emotions. It therefore might be upsetting for shareholders if the CEO were paid generously.

In Summary...

Jim Clemmer is paid around the same as most CEOs of similar size companies.

We'd say the company can boast of its EPS growth, but we find the returns over the last three years to be lacking. We'd be surprised if shareholders want to see a pay rise for the CEO, but we'd stop short of calling their pay too generous. Whatever your view on compensation, you might want to check if insiders are buying or selling AngioDynamics shares (free trial).

Important note: AngioDynamics may not be the best stock to buy. You might find something better in this list of interesting companies with high ROE and low debt.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.